一致Ｂ：2022年第一季度报告（英文）.PDF

1、1 Stock Code:000028/200028 Notice No.:2022-23 Short Form of the Stock:Sinopharm Accord/Accord B China National Accord Medicines Corporation Ltd.The First Quarterly Report for 2022 The Company and whole members of the BOD guarantee that the information disclosed is true,accurate and complete,and ther

2、e are no any fictitious records,misleading statements or important omissions.Important content reminder:1.Board of Directors,Supervisory Committee,all directors,supervisors and senior executives of China National Accord Medicines Corporation Ltd.(hereinafter referred to as the Company)hereby confirm

3、 that there are no any fictitious statements,misleading statements,or important omissions carried in this report,and shall take all responsibilities,individual and/or joint,for the reality,accuracy and completion of the whole contents.2.Principal of the Company,Person in Charge of Accounting Works a

4、nd Person in Charge of Accounting Organ(Accounting Officer)hereby confirm that the Financial Report of the First Quarterly Report is authentic,accurate and complete.3.Whether the First Quarterly Report has been audited or not Yes No I.Main financial data(i)Main accounting data and financial indexes

5、Whether it has retroactive adjustment or re-statement on previous accounting data or not Yes No Current Period Same period of last year Changes of this period over same period of last year Operating income(RMB)17,150,856,946.54 16,049,966,325.75 6.86%Net profit attributable to shareholders of the li

6、sted company(RMB)252,361,872.69 328,800,560.24-23.25%Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses(RMB)242,244,636.06 321,593,612.98-24.67%Net cash flow arising from operating activities(RMB)-217,452,223.38-306,748,999.24 29.11%Basic ear